Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05694793

Trial for Reliability of Urodynamics SysTem

The goal of this prospective trial is to assess the safety and reliability of the Glean Urodynamics System (GUS) in adult females with lower urinary tract symptoms. The main question[s] it aims to answer are:

• What is GUS's ability to safely and reliably conduct wireless, catheter-free monitoring of vesical pressure compared to the vesical pressures collected with conventional urodynamics?

Participants will undergo a conventional urodynamics exam, a simultaneous urodynamics exam with GUS, ambulatory urodynamics with GUS, and extended home monitoring with GUS.

Researchers will compare GUS data with that from a conventional urodynamics exam.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Tri Valley Urology Medical Group, Murrieta, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female patient must be ≥ 18 years of age
  • Patient is a candidate for urodynamics per standard of care
  • Patient or patient's legally authorized representative is able to provide informed consent

Exclusion criteria

  • Pregnant (as confirmed by urine pregnancy test or medical history) or breastfeeding, pregnant within the past 6 months or intend to become pregnant during the study period
  • Patient has one or more symptoms indicative of a urinary tract infection (UTI) (i.e., fever, costovertebral angle pain or tenderness, suprapubic tenderness, worsening urinary frequency, worsening urgency, and/or dysuria).
  • Patient has history of recurrent UTIs (≥ 3 episodes in previous 12 months).
  • Patient has used antibiotics within the past 7 days from the baseline/screening visit.
  • Patient diagnosed with neurogenic LUTS (which may be associated with one or more of these conditions: normal-pressure hydrocephalus, cerebral palsy, spinal cord injuries, traumatic brain injury, stroke, Parkinson's disease, multiple sclerosis, meningomyelocele, spina bifida, dementia, Guillain-Barre syndrome, and tumors involving the central nervous systems or spine).
  • Patient diagnosed with interstitial cystitis (IC), bladder pain syndrome, painful bladder syndrome or any etiology of chronic pelvic pain syndrome (CPPS).
  • Patient with a urostomy.
  • Patient has an atypical anatomic structural variation or has had a previous surgical intervention that has permanently changed structural anatomy anywhere along their lower urinary tract (urethra, pelvic floor, urethral sphincter, and/or bladder wall).
  • Patient who has from one or more major strictures in the urethra.
  • Patient has a Pelvic Organ Prolapse Quantification (POP-Q) of Grade III or higher (i.e., most distal portion of the prolapse protrudes more than 1 centimeter below the hymen).
  • Patient with a colostomy.
  • Patient with any abnormal or concerning rectal or vaginal conditions such as ongoing anal fissures, rectocele, fistula, active herpes, active yeast infections, or vaginitis.
  • Patient has a known inability to void or is in complete retention.
  • Subjects who, at the principal investigator's determination, would not be appropriate for this study

Treatment and study plan

Glean Urodynamics System

Device

Wireless, catheter-free urodynamics system

Other names: GUS

Primary outcomes

  1. Safety

    Time frame: From date of enrollment to study exit (up to 43 days)

    Proportion of participants experiencing a qualifying adverse event attributable to the investigational device

Secondary outcomes

  1. Vesical pressure

    Time frame: during the procedure/surgery

    Vesical pressure

Sponsors and collaborators

Lead sponsor

Bright Uro

Industry

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registry information

Acronym: TRUST-1

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 23, 2023
Registry last updated
Jun 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.